Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Popped Today

By Joe Tenebruso - Mar 16, 2021 at 1:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech just launched a large clinical trial of its coronavirus vaccine in kids.

What happened

Shares of Moderna (MRNA -4.97%) climbed on Tuesday after the biotechnology company announced the start of a clinical trial for its COVID-19 vaccine in children aged 6 months to 11 years. As of 12:45 p.m. EDT, Moderna's stock price was up more than 8%. 

So what 

Moderna's vaccine, mRNA-1273, is currently authorized for emergency use in adults aged 18 and older. The drugmaker began testing its safety and effectiveness in adolescents 12 to 17 in December. And on Tuesday, Moderna said it dosed the first participants in a phase 2/3 study of mRNA-1273 in younger children.

Moderna plans to enroll roughly 6,750 participants in the study. Each child will receive two doses of mRNA-1273 given 28 days apart, with the first at one of three dose levels: 25 micrograms, 50 micrograms, or 100 micrograms. The participants will be monitored for one year after their second dose.

A person is pointing to an upwardly sloping line that's above two other lines.

Moderna's share price rose sharply on Tuesday. Image source: Getty Images.

The National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) will help to conduct the trial.

"We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population," Moderna CEO Stephane Bancel said in a press release.

Now what

Safe and effective coronavirus vaccines such as mRNA-1273 are helping to reduce the spread of COVID-19 around the world. However, the health crisis will not end until children can be protected along with adults. This makes Moderna's new pediatric vaccine study an important step toward an eventual end to the coronavirus pandemic.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.